ivabradine hydrochloride · Amgen Inc · NDA 206143, 209964
Corlanor
Earliest generic entry, as listed · earliest of 3 marketed strengths
12 Dec 2026
Other strengths are listed to 12 Jun 2027; no marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7867996.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7867996 | — | 12 Jun 2027 |
| US 7867996 | substance, product, use U-1694 | 12 Dec 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 24 Oct 2026Enters 12-month window basis: patent · 206143-00212 Jun 2027
- 24 Oct 2026Enters 12-month window basis: patent · 206143-00112 Jun 2027
- 24 Oct 2026Enters 12-month window basis: patent · 209964-00112 Dec 2026
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206143 · 001 · RLD · discontinued | tablet, oral | EQ 5MG BASE | 12 Jun 2027 |
| 206143 · 002 · RLD · discontinued | tablet, oral | EQ 7.5MG BASE | 12 Jun 2027 |
| 209964 · 001 · RLD · discontinued | solution, oral | 5MG/5ML (1MG/ML) | 12 Dec 2026 |
Expired or delisted (8)
- US 7361649 · — · 22 Aug 2026
- US 7361650 · — · 22 Aug 2026
- US 7879842 · — · 22 Aug 2026
- US 7361649 · substance, product, use U-1694 · 22 Feb 2026
- US 7361650 · substance, product, use U-1694 · 22 Feb 2026
- US 7879842 · substance, product, use U-1694 · 22 Feb 2026
- PED · 22 Oct 2026
- ODE-234 · 22 Apr 2026